Restasis® / Cequa®
Ophthalmic cyclosporine is an immunomodulator that increases tear production in patients with dry eye disease associated with ocular inflammation.
| Dosage Form | Ophthalmic Emulsion / Solution (Single-Use Vials) |
| Strength | 0.05% (Restasis); 0.09% (Cequa) |
| Storage | Store at 15–25°C. Do not freeze. |
| Category | Ophthalmics |
| Availability | Available for Transfer |
Dry eye disease (to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation).
Calcineurin inhibitor that suppresses T-cell activation and reduces inflammatory cytokine production in the lacrimal gland, restoring tear production.
Each Burrard Pharmaceuticals technology transfer package for Cyclosporine (Ophthalmic) includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.